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Abstract
The gut microbiota acts as a real organ. The symbiotic 
interactions between resident micro-organisms and the 
digestive tract highly contribute to maintain the gut 
homeostasis. However, alterations to the microbiome 
caused by environmental changes (e.g. , infection, diet 
and/or lifestyle) can disturb this symbiotic relationship 
and promote disease, such as inflammatory bowel 
diseases and cancer. Colorectal cancer is a complex 
association of tumoral cells, non-neoplastic cells and a 
large amount of micro-organisms, and the involvement 
of the microbiota in colorectal carcinogenesis is 
becoming increasingly clear. Indeed, many changes in 
the bacterial composition of the gut microbiota have 
been reported in colorectal cancer, suggesting a major 
role of dysbiosis in colorectal carcinogenesis. Some 
bacterial species have been identified and suspected 
to play a role in colorectal carcinogenesis, such as 
Streptococcus bovis , Helicobacter pylori , Bacteroides  
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fragilis , Enterococcus  faecalis , Clostridium  septicum , 
Fusobacterium spp. and Escherichia  coli . The potential 
pro-carcinogenic effects of these bacteria are now 
better understood. In this review, we discuss the 
possible links between the bacterial microbiota and 
colorectal carcinogenesis, focusing on dysbiosis and 
the potential pro-carcinogenic properties of bacteria, 
such as genotoxicity and other virulence factors, 
inflammation, host defenses modulation, bacterial-
derived metabolism, oxidative stress and anti-
oxidative defenses modulation. We lastly describe 
how bacterial microbiota modifications could represent 
novel prognosis markers and/or targets for innovative 
therapeutic strategies.
Key words: Colorectal cancer; Gut microbiota; Dysbiosis; 
Cyclomodulin; Oxidative stress
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Core tip: The gut microbiota acts as a real organ and 
many changes in its composition have been reported 
in colorectal cancer. The pro-carcinogenic properties 
of bacteria are now better understood. In this review, 
we discuss possible links between the bacterial 
microbiota and colorectal carcinogenesis, focusing on 
the dysbiosis-causing and pro-carcinogenic properties 
of bacteria, such as genotoxicity, inflammation, and 
oxidative stress. We lastly detail how microbiota 
modifications may represent novel prognosis markers 
and/or targets for innovative therapeutic strategies.
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INTRODUCTION
Colorectal cancer (CRC) is a complex association 
of tumoral cells, non-neoplastic cells (i.e., stromal 
cells) and a large number of micro-organisms. The 
microbiota may be linked to carcinogenesis via various 
mechanisms and could lead to the development of 
novel prognosis markers and/or targets for innovative 
therapeutic strategies.
GUT MICROBIOTA IN HEALTH
What is the gut microbiota?
Approximately 100 trillion micro-organisms (including 
bacteria, viruses and fungi) reside in the adult human 
gut and constitute the microbiota[1,2]. The composition 
of the microbiota is rather stable along the length of 
the gut, but the absolute number of micro-organisms 
varies considerably between the mouth and rectum[3]. 
The gut microbiota consistently differs among between 
individuals. It is acquired during the first stages of 
life via the commensal flora from the mother’s skin, 
vagina and feces, and matures primarily during the 
first two years. Microbiota development is the result 
of interactions between physiological process in the 
host and micro-organisms that are introduced from the 
environment[4-6]. After the initial stages, the microbiota 
stabilizes and maintains a consistent composition, 
despite some fluctuations throughout adulthood 
in response to environmental, developmental and 
pathological events[7,8]. In the elderly, the microbiota 
composition changes gradually but can maintain similar 
physiological functions[9-12]. The early acquisition of a 
diverse and balanced microbiota is likely critical for 
the development and maturation of a healthy immune 
system, as suggested by immune abnormalities in 
germ-free animals raised in bacteria-free conditions[4,13]. 
The colon is colonized by approximately 103 different 
microbial species and this colonic microbiota is mostly 
represented by bacteria[7,9,14]. Indeed, the colon con-
tains approximately 1014 bacteria (70% of the host’s 
microorganisms)[15,16]. This review will therefore focus 
on the impact of bacteria in CRC.
Most bacteria cannot be cultured, but modern 
molecular approaches can be used to identify and 
classify bacteria such as 16S ribosomal RNA (16S 
rRNA) sequencing from feces or digestive tissues 
can be used to identify and classify bacteria. The 
microbiota can be divided according to location in the 
gut. Specifically, microbes in the lumen are referred 
to “luminal flora”, whereas microbes that penetrate 
the mucosal layer overlying the intestinal epithelium 
are referred to “mucosa-associated flora”[16]. Indeed, 
thick mucus layers protect enterocytes from excessive 
exposure to microorganisms and dietary antigens 
along the length of the intestine, particularly in the 
colon, thus preventing hypersensitivity responses[17]. 
Moreover, the ratio of anaerobes to aerobes is lower at 
the mucosal surfaces than in the lumen. In addition, 
the collection of “fecal flora” from the feces is a non-
invasive technique that facilitates sampling of colonic 
microbiota. These bacteria are representative of distal 
colonic colonization but differ from proximal “associated” 
flora[18]. It is essential to note that the composition 
of murine gut microbiota is quite similar to that in 
humans, lending translational relevance to mouse 
experimental models of gastrointestinal disease[19,20]. 
Actually, more than 50 different phyla and 500 bacterial 
species may comprise the human normal commensal 
gut microbiota. Although the exact num ber of species 
and the amount of variability among individuals 
remain to be characterized[21,22], these factors are 
likely highly dependent on lifestyle, diet and host 
genotype[23,24]. Some bacterial species are regularly 
recovered from different individuals, and the human 
gut microbiota is dominated by 3 primary phyla: 
Firmicutes (30%-50%), Bacteroidetes (20%-40%) 
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and Actinobacteria (1%-10%). Strict anaerobes, 
including Bacteroides, Eubacterium, Bifidobacterium, 
Fusobacterium, Peptostreptococcus and Atopobium[25], 
represent a major portion of the gut microbiota, 
whereas facultative anaerobes, such as Lactobacilli, 
Enterococci, Streptococci and Enterobacteriaceae, 
constitute a minority (about 1000-fold lower levels). 
The fact that composition significantly vary along the 
gut should also be highlighted, especially given that 
Bacteroidetes and Actinobacteria represent more than 
90% of bacterial phyla in the colon but only 50% in 
the small intestine, which contains approximately 40% 
Firmicutes species[26].
Microbiota and gut homeostasis
The gut microbiota constitutes a natural defensive 
barrier to infection. Moreover, the microbiota is involved 
in numerous protective, structural and metabolic 
roles in the intestinal epithelium and plays a large 
role in maintaining gut homeostasis. The microbiota 
is involved in several physiological functions[27]. The 
impact of enteric bacteria on intestinal physiology has 
been studied primarily in germ-free animals raised 
in bacteria-free conditions. Such animals are more 
susceptible to infections and have reduced vascularity, 
digestive enzyme activity, muscle wall thickness, 
cytokine production and serum immunoglobulin levels, 
smaller Peyer’s patches and fewer intraepithelial 
lymphocytes[28]. The reconstitution of a gut microbiota 
in germ-free mice is sufficient to restore the mucosal 
immune system[29] and affects the expression of 
various host genes that can impact nutrient uptake, 
metabolism, angiogenesis, mucosal barrier function 
and development of the intestinal nervous system[30]. 
Moreover, commensal bacteria influence the normal 
development and function of the mucosal immune 
system[31,32], such as the humoral components[33]. 
These bacteria also modify T-cell repertories and 
T-helper-cell cytokine profiles[34,35]. Such data support 
a possible influence of gut microbiota composition on 
individual variations in immunity.
The structural role of gut microbiota on the 
intestinal epithelium is increasingly evident and has 
been studied primarily in germ-free mice. These 
animals present longer intestinal villi, associated with 
crypt atrophy, slower renewal of epithelial cells and 
decrease of angiogenesis phenomenon[3]. Furthermore, 
it has been reported that mucosa and muscle wall 
thickness were decreased in these mice[28] and that 
microbiota enhanced crypt cell turnover in a CRC-
predisposed mouse model[36].
Furthermore, the gut microbiota is involved in 
metabolic functions[27]. For example, the microbiota 
can participate in (1) anaerobic carbohydrate 
fermentation through the production of CO2, H2, CH4 
and short-chain fatty acids (e.g., butyrate, propionate 
and acetate); and (2) proteolytic fermentation via 
metabolites such as phenolic compounds, amines, 
ammonia, N-nitroso compounds and indoles. These 
effects can impact on gene expression, intestinal 
epithelial cell differentiation and proliferation, and can 
also mediate vitamin synthesis, ion absorption and 
mucus production[27,35,37,38]. This complex metabolic 
activity also increases the yield and storage of energy 
from dietary sources, regulates fat storage, helps to 
provide absorbable substrates for both the host and 
the microbiota, and is involved in bacterial growth 
and proliferation[37-40]. Some of produced metabolites, 
especially during proteolytic fermentation, can be toxic 
to the host[27,41,42].
In addition to immune, structural, and metabolic 
functions, the commensal microbiota inhibits gut 
colonization of intruding pathogens and ensures 
“colonization resistance” or “microbial interference”[43]. 
The involved mechanisms of these effects remain 
unclear but likely involve competition with adhesion 
receptors, stabilization of the gut mucosal barrier, 
competition for nutrients and the production of 
anti-microbial substances[27]. Indeed, alterations in 
colonization resistance due to, e.g., pathogens or 
antibiotics treatment, probably increase the risk of 
gastrointestinal affections. 
MICROBIOTA AND COLORECTAL 
CANCER
Geographic variability of the incidence of CRC highly 
suggests the involvement of certain environmental 
risk factors, such as high-fat diets, obesity or living 
in a Western country[44,45]. Moreover, Knudson’s two-
hit hypothesis suggests that host factors play an 
important role in the predisposition to carcinogenesis. 
In this scenario, a second environmental hit can lead to 
uncontrolled cellular proliferation[46]. Indeed, growing 
attention has been given to the role of microbial 
infection in carcinogenesis in recent decades, and 
microbes are suspected to be involved in approximately 
20% of cancers[47], especially CRC[48]. Concerning 
digestive cancers, even if some pathogens, such as 
Helicobacter pylori (H. pylori), have been directly and 
strongly linked to gastric cancer[49], possible infectious 
cause in CRC remains controversial. It is becoming 
increasingly clear, however, that pathogens play a role 
in colorectal carcinogenesis[50]. Interestingly, bacteria 
levels in the colon are one million-fold higher than 
in the small intestine, and approximately 12-fold 
more cancers develop in the former than in the 
latter, suggesting a potential role of gut microbiota 
in colorectal carcinogenesis[51]. The first observation 
linking gut microbiota with CRC was reported in 1975 in 
germ-free rats that developed less chemically induced 
colorectal tumor than conventional rats[52]. These 
results have been reproduced in CRC-predisposed 
mice[36,53]. Contrary to gastric carcinogenesis, which 
seems to result from a single pathogen, the following 
differing hypotheses have emerged to explain the 
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Interestingly, in this study, most of patients had 
asymptomatic colorectal tumors that were occasionally 
benign adenomas, suggesting the involvement 
of S. bovis at an early step of CRC development. 
However, there are contrasting results in studies of the 
association between S. bovis and CRC; such differences 
could be due to variations in the collection of feces, 
sample processing, bacterial culturing or the molecular 
analysis of fecal samples[66,86,87].
Studies that confirmed the association between 
S. bovis infection and CRC reported prevalences from 
33% to 100% of S. bovis with underlying CRC[88]. It 
was shown that the mucosal detection of S. bovis 
could be a better tool than fecal level to assess its 
presence in patients with CRC[27,89]. More recently, 
Abdulamir et al[90] used molecular techniques to 
show increased S. bovis in colorectal adenomas and 
CRC tissues, strengthening the possible involvement 
of this pathogen in colorectal carcinogenesis. The 
mechanisms behind this link remain unclear, but these 
three hypotheses have been reported: (1) S. bovis 
adheres to both normal epithelial and neoplastic cells; 
(2) this species attains a competitive growth advantage 
in a tumor microenvironment by foraging on tumor 
metabolites; and (3) S. bovis induces inflammation 
and/or pro-carcinogenic pathways, leading to tumor 
progression, especially from pre-malignant tumors[27]. 
Thus, the fact that increase in the numbers of S. 
bovis probably occurs at an early step in colorectal 
carcinogenesis could lead its use for early detection 
of CRC[91]. Moreover, these results directly impact 
clinical practice, leading to recommended colorectal 
endoscopic exploration in all patients presenting with S. 
bovis infection.
H. pylori
H. pylori has been directly and strongly linked to 
gastric cancer[49] and has recently been classified 
as a carcinogen of the gastrointestinal tract by the 
International Agency for Research on Cancer. The 
role of H. pylori in colorectal carcinogenesis remains 
controversial due to differences between studies 
with respect to the H. pylori strains and their specific 
virulence factors. A meta-analysis of 11 studies 
conducted between 1991 and 2002 was published by 
Zumkeller et al[69] and reported a 1.4-fold increased 
risk of CRC in patients presenting with a H. pylori 
infection. More recently, Guo et al[92] reported a 
statistical association between H. pylori and colorectal 
adenomas in a meta-analysis of 7679 Asian patients. 
This result suggested a carcinogenic role of H. pylori 
at an early stage of carcinogenesis. The presence of 
high levels of H. pylori has been reported in CRC tissue 
using a specific 16S rDNA polymerase chain reaction 
(PCR) assay and pyrosequencing[67]. Jones et al[68] 
analyzed paraffin-embedded tissue blocks of normal 
colonic mucosa, adenomas and adenocarcinomas 
from 180 patients. The results indicated a significant 
contribution of bacteria to CRC: (1) a dysbiotic 
microbial community with pro-carcinogenic features 
are capable of remodeling the microbiome as a whole 
to drive pro-inflammatory responses and epithelial cell 
transformation, leading to cancer; and (2) the “driver-
passenger” theory, wherein intestinal bacteria, termed 
“bacteria drivers”, initiate CRC by inducing epithelial 
DNA damage and tumorigenesis, in turn promoting the 
proliferation of passenger bacteria that have a growth 
advantage in the tumoral microenvironment[50,54]. 
Studies in mouse models of altered immune and inflam-
matory responses suggest that dysbiosis could be 
sufficient to promote cancer[55,56]. It is thus likely that 
the immune system is a key factor in the interactions 
between the gut microbiota and CRC. In addition to the 
impact of specific pathogens on carcinogenesis, the high 
redundancy of gut microbiota at a metagenomic level 
suggests that dysbiosis could exert pro-carcinogenic 
effects[57]. These properties could be due to interactions 
between different emergent bacterial strains activating 
similar pathways. However, the mechanisms that 
contribute to dysbiosis and to alterations in microbial 
richness are not well understood, and it is unknown 
whether dysbiosis is a cause or a consequence of CRC. 
Indeed, the CRC microenvironment is characterized by 
host-derived immune and inflammatory responses that 
could impact on microbial regulation, alter microbiota 
composition, and favor the outgrowth of specific 
bacteria that potentially have carcinogenic effects[58]. 
Dysbiosis in CRC could thus result in selection of 
microbiota composition via a tumor-linked microenvi-
ronment, with the emergence of “keystone pathogens” 
that have strong effects on bacterial composition and 
subsequently amplify dysbiosis[59]. 
With the 16S rRNA sequencing of bacteria from 
the feces or digestive tissues, numerous studies have 
reported colonic dysbiosis in patients presenting with 
CRC[18,60-64]. At present, there is no consensus with 
respect to the modifications observed in CRC, which 
are listed in Table 1. However, some bacterial species 
have been identified and are suspected to play a 
role in colorectal carcinogenesis[27,54]. These species 
primarily include Streptococcus bovis (S. bovis)[62,65,66], 
H. pylori[67-69], Bacteroides fragilis (B. fragilis)[61,62,70-72], 
Enterococcus faecalis (E. faecalis)[62,73], Clostridium 
septicum (C. septicum)[74-76], Fusobacterium spp.[77-79] 
and Escherichia coli (E. coli)[80-82].
S. bovis/gallolyticus
S. bovis was the first bacteria indirectly associated 
with CRC. Indeed, McCoy et al[83] reported the first 
recognized case of enterococcal endocarditis associated 
with CRC in 1951. This association was later confirmed 
by Hoppes et al[84], who reported that approximately 
two-thirds of S. bovis endocarditis cases were 
associated with gastrointestinal disease. In addition, 
Klein et al[85] reported a 5-fold increased incidence 
of CRC in patients presenting such endocarditis. 
Gagnière J et al . Microbiota and colorectal cancer
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increase in colonic mucosa-associated colonization by 
H. pylori in adenomas and adenocarcinomas compared 
to normal mucosa[68]. 
Although the role of H. pylori in gastric carci-
nogenesis has been better studied and described 
than its involvement in colorectal carcinogenesis, 
some hypotheses can be extrapolated from the 
pathophysiology of bacteria-linked gastric cancer. 
Bacterial cytotoxin-associated gene A (CagA) and 
vacuolating cytotoxin A (VacA) are encoded by patho-
genicity islands in some H. pylori strains and may 
induce the activation of inflammation pathways and 
cellular proliferation in gastric cancer[93]. Shmuely et 
al[94] reported that patients presenting with seropositivity 
for CagA-positive H. pylori strains had a significantly 
increased risk of CRC. Another hypothesis is the direct 
and indirect production of pro-oxidative reactive oxygen 
and nitrogen species by some H. pylori strains that 
could participate to colorectal carcinogenesis[49].
B. fragilis
B. fragilis are common anaerobic bacteria that are 
detected in up to 80% of children and adults but 
which represent less than 1% of gut microbiota[95,96]. 
There are two molecular subtypes of B. fragilis, 
nontoxigenic or enterotoxigenic, with the latter known 
to be responsible in diarrheal illnesses in humans, 
especially children[97]. Enterotoxigenic B. fragilis is 
easily detected in fecal samples of up to 40% of 
healthy adults, facilitating studies on the role of these 
bacteria in gastrointestinal diseases[98]. Indeed, some 
studies have reported increased colonic colonization 
by B. fragilis in patients presenting with CRC[61,62]. For 
example, Sobhani et al[61] performed pyrosequencing 
Table 1  Summary of 16S rRNA sequencing and qPCR analyses of colonic microbiota variations in colorectal cancer
Variation in CRC Phyla Genus/species Population Ref.
Fecal flora
   ↑ Enterococcus Faecalis 20 CRC/17 C [73]
   ↑ Proteobacteria Porphyromonas/Escherichia/Shigella Enterococcus/
Streptococcus/Peptostreptococcus
46 CRC/56 C [62]
Bacteroides fragilis
   ↑ Bacteroides/Prevotella 60 CRC/119 C [61]
   ↑ Peptostreptococcus/Mogibacterium 21 CRC/22 C [18]
Anaerococcus/Slakia/Paraprevotella
Anaerotruncus/Collinsella/Desulfovibrio
Eubacterium/Porphyromonas
   ↑ Bacteroidetes Atopobium/Porphyromonas 47 CRC/94 C [63]
Fusobacteria Fusobacterium
   ↑ Fusobacteria Fusobacterium/Bacteroides 19 CRC/20 C [64]
   ↑ Bacteroides/Fusobacterium 46 CRC/63 C [214]
Alistipes/Escherichia/Parvimonas/Bilophila
   ↓ Faecalibacterium prauznitsii 20 CRC/17 C [73]
   ↓ Bacteroidetes Bacteroides vulgatus/Bacteroides uniformis 46 CRC/56 C [62]
Roseburia/Butyrate-producing bacteria
   ↓ Faecalibacterium prauznitsii/Roseburia 19 CRC/20 C [64]
   ↓ Firmicutes (clostridia) Ruminococcus 47 CRC/94 C [63]
   ↓ Ruminococcus/Bifidobacterium/Streptococcus 46 CRC/63 C [214]
Tumor-associated flora
   ↑ Bacteroidetes Coriobacteriae/Roseburia 6 CRC/6 AM [14]
Fusobacterium/Faecalibacterium
Butyrate-producing bacteria
   ↑ Bacteroides 22 CRC/22 C [61]
   ↑ Fusobacterium 95 CRC'95 AM [106]
   ↑ Bacteroidetes Bacteroides/Prevotella/Streptococcus 27 CRC [18]
Fusobacteria Fusobacterium/Peptostreptococcus 27 intestinal lumen
Proteobacteria Morganella/Porphyromonas
   ↑ Fusobacterium 55 CRC/55 AM [109]
   ↓ Firmicutes Shigella/Citrobacter/Serratia/Salmonella 6 CRC/6 AM [14]
   ↓ Firmicutes Lactobacillus/Roseburia/Pseudobutyrivibrio 27 CRC [18]
27 intestinal lumen
   ↓ Bacteroidetes 95 CRC/95 AM [106]
Firmicutes (clostridia)
Mucosa-associated flora
   ↑ Fusobacterium/Porphyromonas 32 CRC [18]
Peptostreptococcaceae/Gemella 22 C (swab)
Mogibacterium/Klebsiella
   ↓ Faecalibacterium/Blautia/Anaeroslipes 32 CRC [18]
Lachospira/Bifidobacterium 22 C (swab)
CRC: Colorectal cancer; C: Control patients; AM: Adjacent tumor, normal mucosa of patients with CRC. 
Gagnière J et al . Microbiota and colorectal cancer
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on stools from 179 patients with CRC or controls who 
had a normal colposcopy. The results indicated more 
colonization by B. fragilis in patients presenting with 
CRC than in control patients[61]. Most of enterotoxigenic 
B. fragilis strains detected in mucosal samples from 
patients with CRC harbored the bft gene, which 
encodes the bacterial toxin B. fragilis toxin (BFT). This 
toxin is involved in the pathogenicity of enterotoxigenic 
B. fragilis[99,100]. Indeed, the involvement of BFT in 
colorectal carcinogenesis is becoming increasingly 
evident as this toxin directly affects pathways that lead 
to increased cell proliferation, the epithelial release of 
pro-inflammatory effectors, and DNA damage in in 
vitro and CRC-predisposed mouse models[70-72].
E. faecalis
E. faecalis is a facultative anaerobic commensal 
bacterium of the oral cavity and the gastrointestinal 
tract. Recently, this species has emerged as a human 
pathogen[101]. Balamurugan et al[73] performed 16S 
rRNA real-time PCR from the feces of patients with 
CRC and healthy volunteers. The authors reported 
significantly higher E. faecalis fecal populations in 
patients with CRC compared to healthy controls[62,73]. 
These results were confirmed more recently by Wang 
et al[62]. The mechanisms linking E. faecalis to colorectal 
carcinogenesis remain unclear, but the production 
of pro-oxidative reactive oxygen species (ROS) by 
E. faecalis has been described in cellular and animal 
models[102,103]. Moreover, E. faecalis can trigger colitis, 
dysplasia and CRC in a susceptible interleukin (IL)-10-/- 
mouse model[104].
C. septicum
C. septicum is a rare cause of bacteremia (less 
than 1%). As for S. bovis endocarditis, C. septicum 
infections have been clinically linked to CRC[76]. Indeed, 
it has been reported that gastrointestinal disease and/
or colorectal malignancies can be found in up to 40% 
of patients presenting with C. septicum infections[74,75]. 
Hermsen et al[75] reported an analysis of 320 cases 
of C. septicum infections, of which more than 40% 
had a gastrointestinal origin, primarily malignant. The 
underlying mechanisms of this association remain 
unknown, but one hypothesis is that the hypoxic and 
acidic tumor microenvironment favors the germination 
of C. septicum spores via ingestion of contaminated 
food[27,105]. However, no direct involvement of C. 
septicum in colorectal carcinogenesis has been well 
defined.
Fusobacterium nucleatum
Fusobacterium nucleatum (F. nucleatum) is an 
anaerobic Gram-negative pathogenic bacterium 
that recently emerged as a potential candidate for 
CRC susceptibility. Indeed, recent metagenomic 
analyses using whole-genome and bacterial 16S rRNA 
sequencing revealed an enrichment of F. nucleatum 
in colonic tumor-associated microbiota compared to 
adjacent normal mucosa in patients with CRC[106,107]. 
Moreover, other studies found that luminal F. nucleatum 
colonization was higher in patients presenting with 
colorectal adenomas compared to healthy patients. 
An increase of F. nucleatum colonization in adenomas 
compared to adjacent colonic normal mucosa has 
also been reported[77,78]. These data strongly suggest 
that, more than simply being associated with CRC, F. 
nucleatum likely acts at the early steps of colorectal 
carcinogenesis promotion. This effect may be mediated 
via its FadA adhesion and activates the Wnt/β-catenin 
pathway[79]. This hypothesis has been verified in a CRC-
predisposed adenomatous polyposis coli (APC)min/+ 
mouse model. In this animal model, infection with F. 
nucleatum increased tumor multiplicity and selectively 
recruited tumor-infiltrating myeloid cells, which 
can promote tumor progression[77]. Interestingly, F. 
nucleatum is detected in up to 80% of tumor samples. 
The increased colonic colonization of this species has 
been correlated with CRC stage, as has been described 
for other pathogens[108,109]. Indeed, Viljoen et al[109] 
identified significant associations between high-level 
colonization by F. nucleatum and advanced stage Ⅲ-
Ⅳ CRC, as well as with microsatellite instability tumor 
phenotype. These results could lead to further studies 
that explore (1) the role of F. nucleatum in modulating 
the DNA repair systems involved in colorectal carci-
nogenesis; and (2) the potential pathogenic interactions 
between different pathogenic bacterial species.
E. coli
Although E. coli is a commensal bacteria of the 
human microbiota and represents the most common 
cultivable, Gram-negative, aero-anaerobic bacteria in 
the gut, various studies have demonstrated a clear link 
between mucosa-adherent E. coli and CRC[80-82]. E. coli 
belonging to phylogroups B2 and D comprise most of 
the pathogenic strains that express virulence factors, 
and some of these species are involved in chronic 
inflammatory bowel diseases, which are known risk 
factors for CRC[110,111].
Some studies have reported higher levels of colonic 
colonization by mucosa-associated E. coli in patients 
with CRC compared to healthy patients[80,81]. For 
example, Swidsinski et al[81] performed 16S PCR using 
colonic mucosa tissue samples and detected E. coli in 
only 3% of healthy patient biopsies. However, E. coli 
was detected and predominant in 62% and 77% of 
patients presenting with adenomas and carcinomas, 
respectively[81]. A few years later, Martin et al[80] 
reported that more than 70% of mucosa samples from 
patients with CRC were colonized by bacteria, generally 
E. coli. Increased mucosa- and tumor-associated E. 
coli colonization in CRC patients has been confirmed by 
several studies, strongly implicating E. coli in colorectal 
carcinogenesis[82,108,112,113]. 
CRC samples commonly exhibit colonic mucosal 
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E. coli that could express genes (afa, lpfA, eae and/
or cyclomodulin toxins) that confer characteristics 
that are relevant to pathogenesis, including M-cell 
translocation, angiogenesis and genotoxicity[112,114-117]. 
Cyclomodulins such as colibactin, are toxins that 
interfere with the eukaryotic cell cycle and induce DNA 
damage and genomic instability, which are involved 
in colorectal carcinogenesis[118,119]. A pro-carcinogenic 
effect of B2 phylogroup colibactin-producing E. coli has 
been confirmed in mouse models. Specifically, these 
bacteria are involved in inflammation pathways and 
cell proliferation fueling[82,108,120]. Moreover, possible 
interactions between E. coli and DNA repair system 
involved in colorectal carcinogenesis, such as the 
DNA mismatch repair (MMR) system, have been 
described[112,121]. Interestingly, these B2 colibactin-
producing E. coli are preferentially detected in patients 
with CRC[82,108,115,120] and were more prevalent in the 
mucosa of patients presenting with advanced stage 
Ⅲ/Ⅳ CRC than in those with stage Ⅰ CRC[108]. These 
results suggest that E. coli could serve as a prognostic 
factor in CRC. 
SUSPECTED INVOLVED MECHANISMS
As described above, some bacterial species may be 
involved in colorectal carcinogenesis. Many suspected 
involved mechanisms, occasionally shared by different 
species, have been described. These mechanisms 
include bacterial-derived genotoxins, microbial-derived 
metabolism, the modulation of host defenses and 
inflammation pathways, oxidative stress induction, and 
anti-oxidative defense regulation (Figure 1).
Bacterial-derived genotoxins and other bacterial 
virulence factors
During their phylogenetic evolution, bacteria pro-
gressively acquired virulence factors that conferred 
pathogenicity. For example, bacteria developed the 
ability to penetrate the gut mucosal barrier, as well 
as to adhere to and invade intestinal epithelial cells, 
specifically through the use of flagellum, pili, and 
adhesins[110,122,123]. Most of the disease-promoting 
and pro-carcinogenic effects of pathogens depend 
on these virulence factors[58]. Pathogens can interact 
with adhesion molecules. For example, F. nucleatum 
uses the FadA virulence factor to adhere to and 
invade cells[124], thereby activating β-catenin signaling 
pathway and promoting CRC[79]. In the same way, 
certain CRC-associated E. coli strains have acquired 
virulence factors, such as the afa and eae adhesins, 
which confer the ability to adhere to and invade the 
intestinal epithelium[112,116].
Toxins may be involved in colorectal carcinogenesis 
by modulating certain host-derived signaling 
pathways, resulting in the activation of carcinogenesis-
promoting pathways. For example, CagA or VacA 
are produced by some H. pylori strains and increase 
inflammation and cancer rates[125,126]. B. fragilis has 
been associated with CRC[71,127], and BFT is another 
well-described example of a bacteria-derived toxin 
involved in colorectal carcinogenesis. BFT is a 20 
kDa zinc-dependent metalloprotease toxin that is 
grouped into three isotypes, namely, BFT-1, BFT-2 
and BFT-3[100]. These toxins are encoded by a unique 
B. fragilis-specific gene, which was described by 
Moncrief et al[128] in 1995. A recent study reported 
that mucosa-associated BFT-producing B. fragilis were 
more prevalent in late-stage CRC, suggesting possible 
role of BFT in CRC promotion and progression[99]. At 
the molecular level, BFT binds to a specific colonic 
epithelial receptor, activating the Wnt and nuclear 
factor-kappa B (NF-κB) pathways. These effects lead 
to increased cell proliferation, the epithelial release of 
pro-inflammatory mediators, and the induction of DNA 
damage[97,129-132]. Furthermore, in the CRC-predisposed 
multiple intestinal neoplasia APCmin+/- mouse model, 
BFT promotes IL-17-dependent carcinogenesis[127].
Other toxins, named cyclomodulins [cytolethal 
distending toxin (CDT), colibactin, cytotoxic necrotizing 
factor and cycle inhibiting factor], can induce DNA 
damage, interfere with the cell cycle and/or apop-
tosis[82,118,127,133-136]. Only CDT and colibactin can directly 
damage DNA and are linked genomic instability; these 
proteins are therefore considered true genotoxins[118,133]. 
Both CDT and colibactin induce double-strand DNA 
breaks, activate the ataxia telangiectasia mutated 
(ATM)-checkpoint kinase 2 signaling pathway, and lead 
to H2AX histone phosphorylation. These effects result in 
transient G2/M cell cycle arrest and cell swelling.
Most of the Gram-negative bacteria that are 
involved in CRC produce CDT, which is by far the most 
well-characterized bacterial-derived genotoxin[137]. The 
CdtA and CdtC subunits permit the interaction between 
pathogens and host cells; subsequently, the cytoplasmic 
CdtB subunit can translocate to the nucleus, act as a 
DNase and damage DNA[133]. CDT also favors persistent 
gut colonization and induces the production of pro-
inflammatory molecules, such as NF-κB, tumor necrosis 
factor (TNF)-α, IL-6 and cyclooxygenase (COX) 2. These 
factors are involved in many carcinogenic processes. 
CDT has also been reported to induce dysplasia in 
a Helicobacter hepaticus-linked hepatocarcinoma 
mouse model[138,139]. When combined, DNA damage, 
interference with the cell cycle and the modulation of 
pro-inflammatory pathways can lead to mutations that 
are involved in genomic instability in CRC.
Colibactin is another bacterial-derived genotoxin 
that has recently attracted attention. It was first 
described in 2006 by Nougayrède et al[119] but has not 
yet been isolated and purified. Colibactin synthesis and 
activation requires complex machinery that involves 
three non-ribosomal peptide megasynthases (NRPS), 
three polyketide megasynthases (PKS), two NRPS/PKS 
hybrids and at least eight of nine accessory enzymes 
encoded in the pks island[119]. The pks island is found 
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primarily in the Enterobacteriaceae family, especially 
in the E. coli B2 phylogroup[115,119]. Interestingly, 
other micro-organisms, such as Proteus mirabilis and 
Klebsiella pneumoniae, which are associated with 
bacterial-induced colitis and an immunodeficient-
CRC-mouse model, also carry the pks island[140-142]. 
Colibactin induces ROS formation, double-strand DNA 
breaks, and the associated ATM-mediated DNA damage 
response, cell cycle arrest and genomic instability[82,118]. 
Furthermore, colibactin-producing E. coli can enhance 
tumor growth by inducing the emergence of senescent 
epithelial cells secreting growth factors and/or by 
the secretion of pro-tumoral molecules by infiltrating 
cells[58,114,120]. Interestingly, even though toxin-
producing bacteria constitute a minority of the colonic 
microbiota, metatranscriptomic analyses performed on 
human CRC tissues samples reveal a high expression 
of these toxins in the colon[143].
Microbial-derived metabolism affecting carcinogenesis
In addition to the involvement of bacterial virulence 
factors, such as genotoxin production, it has become 
increasingly clear that microbial-derived metabolism 
strongly impacts CRC development[144]. These meta-
bolic activities may affect colorectal carcinogenesis 
via the following several processes: regulating the 
generation of CRC-promoting secondary bile acids; the 
metabolic activation or inactivation of pro-carcinogenic 
compounds, dietary phytochemicals and xenobiotics; 
hormone metabolism; and the modification of 
inflammation pathways[58].
The interplay between diet, bile acids and gut 
microbiota is complex. Indeed, high-fat diets are 
correlated with increased bile secretion and an 
increased risk of CRC[145-147]. Primary bile acids excreted 
into the gut are converted through microbial derived-
metabolism, including hydrolase activities, into se-
condary bile acids. These acids are used by microor-
ganisms as an energy source[148] but are also known to 
be involved in many colorectal carcinogenesis-linked 
process, such as apoptosis, cell proliferation, DNA 
damage induction and tumor promotion[27]. Bernstein 
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et al[146] reported a higher incidence of tumors in bile 
acid-exposed gut in a mouse model. Indeed, bacteria-
transformed bile acids can result in DNA damage by 
the production of pro-oxidative molecules, such as 
ROS and nitrogen species (NOS)[149,150]. Therefore, 
chronic exposure to increased levels of secondary 
bile acids may favor the induction of DNA damage, 
leading to genomic instability, which is involved in CRC. 
Furthermore, strong antimicrobial bile acid activities 
lead to significant changes in the gut microbiota 
composition, with a relative increase in some Gam­
maproteobacteria and Bacteroidetes species that are 
associated with CRC[151].
Some carcinogens are inactivated in the liver 
by glucuronic acid-mediated conjugation and are 
excreted via bile in the digestive tract. In the gut, 
and particularly in the colon, this process may be 
reversed by bacterial β-glucuronidase activity, which 
can lead to CRC. Indeed, Takada et al[152] reported 
a decrease in tumor number with the inhibition of 
bacterial β-glucuronidase activity in a CRC rat model. 
Moreover, fecal β-glucuronidase activity is increased 
in patients with CRC compared to healthy controls[153]. 
These results strongly support the involvement of 
bacterial β-glucuronidase activity in the initiation 
and progression of CRC via the reactivation of toxic 
components. Moreover, bacterial β-glucuronidase 
activity plays a major role in the metabolism of 
xenobiotics and affects the activity and side effects of 
certain antitumor drugs[58,154]. For example, irinotecan, 
a commonly used chemotherapy for CRC that is 
inactivated in the liver, is locally modified in the gut, 
generating intermediate molecules without systemic 
anti-tumor effect and inducing major treatment-
limiting side effects (e.g., severe diarrhea). These 
undesired effects can be prevented with the use of 
antibiotics or bacterial β-glucuronidase inhibitors[155].
Contrary to microbial carbohydrate fermentation, 
which can benefit the host through the generation of 
short chain fatty acids (e.g., butyrate, acetate, pro-
pionate)[156], microbial protein fermentation generates 
potentially toxic and pro-carcinogenic metabolites 
involved in CRC, such as phenols, sulfides, ammonia 
and nitrosamines[58]. It has been reported that protein-
rich and low-carbohydrate diets can lead to the 
increased microbial production of toxic metabolites 
to the detriment of cancer-protective metabolites[157], 
increasing the risk for CRC[158]. However, concentration-
dependent effects on CRC have been described for 
butyrate. At lower concentrations, butyrate appears 
to stimulate epithelial cell proliferation[159], while other 
studies have demonstrated anti-proliferative and anti-
cancer properties of this compound[160]. A subset 
of bacteria, including Bacteroidetes and Firmicutes 
species, produce potentially bioactive substances via 
the degradation of amino acids, especially nitrogenous 
compounds, in the gut[161-163]. These compounds can 
exert carcinogenic effects through DNA alkylation, 
leading to mutations that have been reported in 
Western diet-linked CRC[161-163]. Moreover, sulfides 
produced in the gut by the bacterial reduction of 
dietary sulphate, as well as the metabolism of other 
compounds[164], are enterotoxic[165]. These sulfides have 
genotoxic effects on human cell lines at physiological 
concentrations[166]. These effects occur primarily via 
the induction of ROS formation and DNA damage[167].
Chronic and/or excessive consumption of alcohol 
has been found to be an important risk factor for many 
cancers, including CRC[168]. Microbial metabolism may 
contribute to the toxicity of alcohol, especially in the 
gastrointestinal tract, where aerobic and facultative 
anaerobic bacteria convert ethanol to acetaldehyde[169]. 
Indeed, acetaldehyde is known to be a highly toxic 
and pro-carcinogenic compound with various negative 
effects, ranging from DNA damage and impaired 
DNA excision repair to the degradation of folate. All 
of these effects have been implicated in colorectal 
carcinogenesis[169-171]. The role of microbiota in this 
process has also been reinforced by Homann et 
al[172], who reported that the conversion of ethanol to 
acetaldehyde was inhibited by the use of antibiotics, 
such as ciprofloxacin. This drug kills primarily aerobic 
and facultative anaerobic bacterial populations[172].
Host defense modulation and inflammation
As previously mentioned, the intestinal mucosa 
constitute the first line of defense against gut 
commensal or pathogen bacteria and related microbial 
molecules. Intestinal epithelial cells need to rapidly 
detect the presence of pathogens in order to mount 
a suitable immune response. However, these cells 
also must maintain a moderate immune response 
against or tolerance for non-pathogenic bacteria[173]. 
The maintenance of gut homeostasis and these 
interactions between the host and microbiota involve 
innate immunity receptors, such as Toll Like Receptors 
(TLRs) and Nod Like Receptors (NLRs), which 
recognize particular molecular motifs associated with 
pathogens. The activation of these receptors leads to a 
cellular response, including the activation of MAPK, NF-
κB or PI3K/AKT signaling pathways[174]. The activation 
of these pathways can induce the expression of pro-
inflammatory cytokines (e.g., TNF-α, IL-6, IL-8) and/or 
antimicrobial peptides, all of which are involved in the 
development of an inflammatory response. Indeed, a 
decrease in intestinal tumor number has been reported 
in azoxymethane (AOM)-treated APCMin/+ or IL­10­/­ 
mice invalidated for MyD88 gene, which encodes a 
TLR signaling adaptor[175,176]. However, these results 
remain controversial given that another recent study 
reported that MyD88-/- mice treated with AOM/dextran 
sulfate sodium (DSS) exhibit increased susceptibility to 
colorectal tumors. These results suggest that the role 
of TLR signaling and the host response in CRC differ 
between colitis-associated and chemically induced 
CRC[177]. Moreover, Nod1- or Nod2­-deficient APCMin/+ 
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and AOM/DSS-treated mice exhibit an increase in 
the number of colorectal tumors compared to control 
animals, suggesting the involvement of NLRs in 
colorectal carcinogenesis[55,178]. These results highlight 
the major role of the host immune response to gut 
microbiota in CRC development.
It is now well established that inflammatory 
bowel disease patients, who are known to have an 
increased risk for developing CRC, present many 
changes in their microbiota composition[179-181]. For 
these reasons, the involvement of inflammation in the 
establishment of dysbiosis-related CRC is increasingly 
evident. Some in vivo studies have shown that the gut 
microbiota composition differs between AOM-treated 
and untreated IL­10-/- mice. Moreover the emergence 
of dysbiosis after each cycle of DSS treatment in mice 
treated with AOM has been observed[82,182]. Taken 
together, these data constitute strong evidence that 
inflammation plays an important role in the modulation 
of the microbiota and dysbiosis emergence during 
colorectal carcinogenesis.
However, inflammation could also be linked to 
the host response induce by bacteria during CRC 
development. It has been previously reported in 
a CRC-predisposed APCMin/+ mouse model that 
BFT induces a Th17 pro-inflammatory response, 
which is involved in the development of early-stage 
tumors[127]. Furthermore, the contribution of S. bovis 
to colorectal carcinogenesis is associated with the 
increased expression of pro-inflammatory genes, 
such as IL-1, IL-8 and COX-2[90]. Moreover, APCMin/+ 
and IL-10-/- mice infected with F. nucleatum and 
E. faecalis, respectively, exhibit increased immune 
cell infiltration in tumors and colonic mucosa and 
heightened expression of pro-inflammatory cytokines, 
such as TNF-α, IL-1β, IL-6 and IL-8[77,104,183]. E. coli is 
one of the best-characterized bacteria associated with 
inflammatory bowel disease. An abnormal colonization 
of the gut mucosa by adherent and invasive E. coli 
in inflammatory bowel disease patients has been 
reported[110,111]. Moreover, Raisch et al[184] showed that 
CRC-associated E. coli can induce the expression of 
the pro-inflammatory gene COX-2 in macrophages, 
supporting the bacterial modulation of inflammation in 
colorectal carcinogenesis.
Oxidative stress and anti-oxidative defenses modulation
ROS induction appears to have a major and central role 
in microbiota-linked CRC via the previously described 
mechanisms. ROS can be generated by cells during 
infection and inflammation, as previously discussed, or 
directly by gut microbiota[177]. The induction of ROS is 
known to be a major defense mechanism of infected 
cells, contributing to the elimination of bacteria[48,119]. It 
has been reported in both in vitro and in vivo studies 
that some Enterococci species, especially E. faecalis, 
generate hydroxyl radicals[102,103]. These radicals are 
powerful mutagens that can cause DNA breaks, point 
mutations and protein-DNA crosslinking, all contributing 
to genomic instability in CRC[185-187]. Furthermore, this 
bacterium can induce aneuploidy in colonic epithelial 
cells, and the use of inhibitors of ROS and NOS can 
prevent this effect, supporting the role of bacterial-
induced oxidative stress in colorectal carcinogenesis[82]. 
Moreover, the role of H. pylori in gastric carcinogenesis 
via the induction of oxidative stress has been clearly 
demonstrated[49], and this species is able to both 
produce and induce the production of ROS by immune 
cells. In this manner, H. pylori affects many signal 
transduction pathways in gastric cells and thereby 
promotes gastric cancer. It could thus extrapolate the 
fact that existence of colorectal chemical-, bacterial- 
and/or immune-induced inflammation also induces the 
recruitment of neutrophils and macrophages, which 
are major sources of ROS, leading to the genetic and 
epigenetic alterations involved in CRC[188-190]. The gut 
microbiota also promote host-derived production of 
nitric oxide and its secondary NOS, especially through 
the activation of macrophages in the inflammation 
response, which can induce DNA damage. Some 
bacterial species can directly generate NOS[191]. Sobko 
et al[192,193] reported that Lactobacilli and Bifidobacteria 
generate significant levels of NOS in germ-free and 
monoassociated mice and that a nitrate-enriched 
diet increased NOS production. However, it is not 
clear whether in ROS and NOS produced in vivo are 
sufficiently long lived to diffuse from immune cells to 
the extracellular matrix and subsequently enter the 
nucleus of epithelial cells to induce damage DNA[194].
Oxidative stress is defined by an imbalance 
between the levels of pro-oxidative molecules (e.g., 
ROS and NOS) and the effectiveness of anti-oxidative 
defenses[195]. Oxidative stress results in primarily 
irreversible direct or organic substrate-mediated 
cell damage, including DNA breaks and damage, 
protein aggregation or fragmentation, and cellular 
membranes dysfunction[185,195]. The toxic effects of 
ROS and NOS are thus balanced by various enzymatic 
and non-enzymatic anti-oxidative defenses, which 
help to regulating ROS/NOS production and repair 
mechanisms[196,197]. DNA repair mechanisms are altered 
in CRC[198,199]. Moreover, under specific conditions, 
the balance between pro- and anti-oxidative 
compounds is lost, especially in cases of bacterial 
infection. The bacterial modulation of anti-oxidative 
defenses, especially DNA repair systems, is becoming 
increasingly clear. Mangerich et al[200] reported 
decreased expression of DNA repair and oxidative 
response genes in the colons of colitis-induced CRC 
mice model that were infected with H. hepaticus. 
Moreover, Maddocks et al[112,121] reported in vitro results 
demonstrating the ability of some enteropathogenic 
E. coli strains to downregulate the DNA MMR system 
in infected HT-29 intestinal epithelial cells via post-
transcriptional effect of a secreted effector protein. 
This downregulation of the MMR system led to the 
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accumulation of mutations involved in colorectal 
carcinogenesis[112,121]. Furthermore, a study on APCMin/+ 
MMR-deficient mice strongly supports a possible role 
of an interaction between gut microbiota and MMR 
deficiency in CRC induction[159]. Indeed, Belcheva 
et al[159] reported that (1) altering the microbiota 
composition reduces tumorigenesis; (2) gut microbes 
can fuel the hyperproliferation of MMR-altered intestinal 
epithelial cells; and (3) the MMR pathway has a role 
in regulating APC/β-catenin activity and modulating 
the differentiation of transit-amplifying cells in the 
colon[159]. Moreover, Viljoen et al[109] reported increased 
colonic colonization by F. nucleatum in CRC patients 
with an MMR deficiency-linked microsatellite instability 
phenotype. All of these data strengthen the hypothesis 
of an interaction between the gut microbiota and the 
DNA repair system in colorectal carcinogenesis.
MICROBIOTA IMBALANCE AND CLINICAL 
IMPLICATIONS 
As previously mentioned, the gut microbiota likely 
plays a major role in the promotion and progression of 
CRC via several mechanisms, including inflammation, 
metabolism and genotoxicity. There are therefore 
many possible ways by which to target the microbiota 
in terms of CRC prevention strategies. Indeed, the 
use of probiotics or fecal transplantation protocols 
could combat CRC-associated dysbiosis and thus 
restore eubiosis in chronic diseases, helping to reduce 
microbiota-induced genotoxicity and activation of 
inflammatory, proliferative and pro-carcinogenic 
pathways[58]. However, this microbiota-targeting 
therapy approach has not been well studied in CRC.
Genotoxins are a target of interest in the context 
of CRC treatment. For example, supportive evidence 
has recently been provided that colibactin-producing 
E. coli could be major actors in CRC-related genomic 
instability[58,114,115,119,120]. Colibactin synthesis requires 
the serine enzyme ClbP, which acts as a peptidase 
to produce colibactin NRPS compounds[201-203]. On 
this basis, it has been reported that boronic acid 
compounds, which are potent inhibitors of active serine 
enzymes, suppress the genotoxic activity of colibactin-
producing E. coli in vitro and in vivo[204]. In CRC mice 
model, treatment with such compounds was shown 
to prevent cell proliferation and genotoxin-induced 
tumorigenesis compared to water-treated mice[204].
Changes in gut microbiota composition could 
also lead to an altered host immune response. On 
this basis, some authors have studied the impact of 
the oral administration of probiotics on immunologic 
signaling. These studies have provided supportive 
evidence that the gut microbiota plays an essential 
role in intestinal epigenomic mechanisms of the 
host[205,206]. Moreover, it was reported that the deletion 
of lipoteichoic acid (LTA), a TLR2 ligand, normalizes 
innate and adaptive pathogenic immune responses and 
decreases the number of tumors in a CRC-predisposed 
murine model. It was also reported that LTA-deficient 
Lactobacillus acidophilus (1) decreased inflammation 
and protected against CRC[207]; (2) prevented or 
induced the regression of established colitis and 
polyposis[207,208]; and (3) downregulated downstream 
signaling[209], and stimulated tumor suppressor gene 
expression in CRC cell lines[210]. Furthermore, some 
commensal bacteria, such as Bifidobacterium breve 
and Lactobacillus rhamnosus, inhibit the production 
of pro-inflammatory cytokines and decrease host 
DNA methylation and histone acetylation events 
that are involved in colorectal carcinogenesis[211-213]. 
All of these results underline a feasible microbiota-
targeting therapy approach in CRC through the use 
of probiotics or genetically modified bacteria. Even if 
fecal transplantation has not been well studied in CRC, 
future transplantation studies using germ-free CRC 
animal models likely represent an important next step 
in this line of inquiry.
To provide adequate treatments as part of modern 
personalized medicine, accurate prognosis factor 
have yet to be establish. Prognostic factors in CRC 
primarily depend on morphologic and histologic 
results. Recently, there has been a significant body 
of work involving the gut microbiota as a prognosis 
factor in CRC. Bonnet et al[108] reported increased 
colonic colonization by cyclomodulin-producing E. coli 
in advanced stage CRC, that have been ever described 
by Viljoen et al[109] for enterotoxigenic B. fragilis and 
F. nucleatum. These results support a possible use of 
microbiota CRC prognosis markers that may be used 
to improve patient selection for aggressive, suitable 
treatments.
CONCLUSION
The advent of modern molecular microbiota sequencing 
techniques has strongly improved the characterization 
of microbiota variations in CRC. However, a better 
understanding of the interactions between the host and 
pathogens in colorectal carcinogenesis requires further 
microbiota functional studies, especially with respect 
to metabolomics and RNA sequencing approaches. 
All of the studies published in this regard have been 
performed without classifying tumors according to 
their molecular phenotype. Investigations should 
also consider the heterogeneity of CRC tumors by 
studying microbiota imbalances in relation to molecular 
pathways involved in colorectal carcinogenesis, such 
as chromosomal and microsatellite instabilities or 
CpG island methylator phenotypes. In summary, the 
role of the microbiota in CRC is increasingly evident 
and perhaps represents a new approach towards the 
improved therapeutic management of patients with 
CRC.
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